TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor that recognizes changes in the lipid microenvironment, which may occur during amyloid β (Aβ) accumulation and neuronal degeneration in Alzheimer’s disease (AD). Rare TREM2 variants that affect TREM2 function lead to an increased risk of developing AD. In murine models of AD, TREM2 deficiency prevents microglial clustering around Aβ deposits. However, the origin of myeloid cells surrounding amyloid and the impact of TREM2 on Aβ accumulation are a matter of debate. Using parabiosis, we found that amyloid-associated myeloid cells derive from brain-resident microglia rather than from recruitment of peripheral blood monocytes. To determine the impact of TREM2 deficiency on Aβ accumulation, we examined Aβ plaques in the 5XFAD model of AD at the onset of Aβ-related pathology. At this early time point, Aβ accumulation was similar in TREM2-deficient and -sufficient 5XFAD mice. However, in the absence of TREM2, Aβ plaques were not fully enclosed by microglia; they were more diffuse, less dense, and were associated with significantly greater neuritic damage. Thus, TREM2 protects from AD by enabling microglia to surround and alter Aβ plaque structure, thereby limiting neuritic damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which may represent dystrophic neurons that accumulate over time as a result of ineffective microglial control of AD pathology due to lack of Trem218,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the compaction of protofibrillary Aβ into a dense core plaque, which requires apoE and is promoted by TREM2 (Bales et al., 1997b, 1999; Bien-Ly et al., 2012; Wang et al., 2016; Yuan et al., 2016), could be a protective mechanism that limits neurotoxicity of amyloid deposits once they start to build up in the aging brain.”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trem2 deficiency induces dynamic changes but an eventual increase in plaque and neuritic pathology (Jay et al., 2017; Wang et al., 2015; Wang et al., 2016; Yuan et al., 2016).”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of TREM2 results in impaired plaque trimming, which leads to enlarged plaques with reduced compaction48,49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [48]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 4×
“Brains were isolated 3 h after injection and made into single-cell suspension as previously described (Heneka et al., 2013).”
BackgroundMethodInfluentialIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“However, phenotypic markers of migroglia, such as low expression of CD45 and high expression of the P2Y(12) receptor, are altered upon microglial activation and therefore do not precisely discriminate microglia from monocytes (Butovsky et al., 2014).”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 11×
“…response to Aβ deposits in all AD models, changes in Aβ burden develop more slowly; therefore, the discrepancies in Aβ accumulation may be a result of the varied timing of the analyses—8 mo in 5XFAD mice (Wang et al., 2015) and 3–4 mo in APP PS1-21 mice (Ulrich et al., 2014; Jay et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 1×
“Key pathological features of AD consist of the deposition of amyloid-β peptide (Aβ) and hyperphosphorylated tau aggregates that, together, are linked with synapse loss and neuronal cell death, as well as activation of microglia and astrocytes (Holtzman et al., 2011).”
BackgroundSelf-citationAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“Recent genome-wide association studies have identified rare variants of genes that encode immune receptors as risk factors (Guerreiro and Hardy, 2014; Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“Given that brain-resident microglia are capable of self-renewal and expansion (Gomez Perdiguero et al., 2013; Greter and Merad, 2013; Prinz and Priller, 2014), we next sought to determine if microglia associated with plaques resulted from the proliferation of resident microglia.”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 2×
“TREM2 signaling promotes survival, proliferation, phagocytosis, and secretion of cytokines and chemokines (Takahashi et al., 2005; Otero et al., 2009; Wang et al., 2015).”
BackgroundThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727 · cited 2×
“The origin of nonfamilial AD is less well understood and may depend on a combination of genetic and nongenetic risk factors (Tanzi, 2012).”
Background
Cited by
Items 501–600 of 838
VEGF controls microglial phagocytic response to amyloid-β
Gea, P. D., Benkeder, S., Bouvet, P., Aimard, M., Chounlamountri, N., Honnorat, J., Do, L.-D., & Meissirel, C. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1264402 · Cited by 19
Loss of TREM2 diminishes CAA despite an overall increase of amyloid load in Tg‐SwDI mice
Zhong, R., Xu, Y., Williams, J. W., & Li, L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14222 · Cited by 16
Updating Neuroimmune Targets in Central Nervous System Dysfunction
Valente, L. A., Begg, L. R., & Filiano, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.013 · Cited by 18
Quarta, A., Berneman, Z. N., & Ponsaerts, P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru0820-536r · Cited by 17
Han, S., Na, Y., Koh, I., Nho, K. T., & Lee, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189865 · Cited by 18
The Role of Immunity in Alzheimer's Disease
McManus, R. M. (2022) · Advanced Biology · doi:10.1002/adbi.202101166 · Cited by 18
Kawabata, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.913693 · Cited by 16
Lana, D., Ugolini, F., & Giovannini, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249441 · Cited by 17
Neurodegeneration Enhances the Development of Arthritis
Lang, S. C., Harre, U., Purohit, P., Dietel, K., Kienhöfer, D., Hahn, J., Baum, W., i, M. H., Schett, G. A., & Mielenz, D. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601472 · Cited by 17
Takalo, M., Jeskanen, H., Rolova, T., Kervinen, I., Hellén, M., Heikkinen, S., Koivisto, H., Jokivarsi, K., Müller, S. A., Koivumäki, E.-M., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03387-6 · Cited by 16
Alzheimer’s disease: Pathophysiology and dental pulp stem cells therapeutic prospects
Xiong, W., Liu, Y., Zhou, H., Jing, S., He, Y., & Ye, Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.999024 · Cited by 17
“This weakening of the response barrier may promote the spread and invasion of Aβ amyloid in the early stages of AD, triggering neuroinflammation (Wang et al., 2016).”
BackgroundVandermeulen, L., Geric, I., Fumagalli, L., Kreir, M., Lu, A., Nonneman, A., Premereur, J., Wolfs, L., Policarpo, R., Fattorelli, N., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00725-9 · Cited by 18
“Several studies demonstrated that the absence of mouse Trem2 aggravates Aβ and Tau pathology, promotes neuritic dystrophy and facilitates Tau seeding in mouse models of AD [98, 99, 101–103].”
BackgroundTherapeutic Targets in Innate Immunity to Tackle Alzheimer’s Disease
Serradas, M. L., Ding, Y., Martorell, P., Kulińska, I., & Castro‐Gomez, S. (2024) · Cells · doi:10.3390/cells13171426 · Cited by 17
“In studies conducted by Wang et al. [98,99], the authors demonstrated that Trem2 deficiency in mouse models of AD ( Trem2 − / − 5xFAD mice) resulted in a reduced clustering of microglia around A β plaques, leading to larger, more diffuse, and less dense plaques.”
BackgroundVasilopoulou, F., Piers, T. M., Wei, J., Hardy, J., & Pocock, J. M. (2024) · FEBS Journal · doi:10.1111/febs.17353 · Cited by 21
“TREM2 is expressed i microglia, the resident immune cells of the brain, and is required for diverse microglia responses in neurodegeneration, including immunometabolic plasticity, phagocytosis, and survival [3 – 6].”
Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 18
“Accordingly, in the absence of TREM2, amyloid plaques are more diffuse with a loose structure [55, 56].”
InfluentialWang, S., & Colonna, M. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1200 · Cited by 17
Self-citationRole of triggering receptor expressed on myeloid cells 2 (TREM2) in neurodegenerative dementias
Shafi, S., Singh, A., Ibrahim, A. M., Alhajri, N., Izneid, T. A., & Pottoo, F. H. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15215 · Cited by 15
“In addition, in vitro studies demonstrated association between TREM2 and Aβ uptake (Wang et al., 2016).”
BackgroundInfluentialWang, T., Liu, X., Wang, X., Hua, F., & Yan, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1739875 · Cited by 14
“Intriguingly, TREM2 deletion attenuates plaque load in early disease stages but exacerbates pathology later (50), supporting a model in which TREM2 enables microglia to surround and condense plaques, thereby limiting neuritic damage (49).”
Pilat, D. J., Le, H., Prokopenko, D., Lin, C.-C. J., Eimer, W. A., Quinti, L., Gavrilles, E. P., Garcia, S. N., Heitman, S. N., McGinty, D., et al. (2026) · Neuron · doi:10.1016/j.neuron.2025.09.032 · Cited by 14
Henningfield, C. M., Soni, N., Lee, R. W., Sharma, R. B., Cleland, J. L., & Green, K. N. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01470-3 · Cited by 19
“This falls in line with previous studies suggesting that microglia-plaque interaction is beneficial in limiting the amount of damage caused by Aβ plaques [13, 18, 62, 69, 70, 73].”
ResultZhou, L., Wang, N., Feng, W., Liu, X., Wu, Q., Chen, J., Jiao, X., Ning, X., Qi, Z., Xu, Z., et al. (2024) · Glia · doi:10.1002/glia.24606 · Cited by 14
“Studies have shown that plaque-associated microglia (PAMs) may help contain A β plaques (Wang, Ulland, et al., 2016).”
Dongre, P., Ramesh, M., Govindaraju, T., & Inamdar, M. S. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03415-5 · Cited by 14
“Microglial Aβ phagocytosis shapes the extent of plaque accumulation and is a critical response to AD pathology [33].”
Knight, A. C., Brill, S. A., Solis, C. V., Richardson, M. R., McCarron, M. E., Queen, S. E., Bailey, C. C., & Mankowski, J. L. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-020-00844-1 · Cited by 16
“…University, School of Medicine, Baltimore, MD, USA 4 Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA mice that TREM2-expressing microglia surround amyloid beta plaques, further suggesting a sequestering and protective role of these cells (Wang et al. 2016).”
Role of TREM2 in the Development of Neurodegenerative Diseases After Traumatic Brain Injury
Zhang, C., & Chen, S. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03094-w · Cited by 14
Apolipoprotein ε in Brain and Retinal Neurodegenerative Diseases
Abyadeh, M., Gupta, V., Paulo, J. A., Sheriff, S., Shadfar, S., Fitzhenry, M. J., Amirkhani, A., Gupta, V. B., Salekdeh, G. H., Haynes, P. A., et al. (2024) · Aging and Disease · doi:10.14336/ad.2023.0312-1 · Cited by 28
Nand, S., Chaturvedi, V. K., Singh, S. P., & Singh, M. P. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00219 · Cited by 14
“On other hand, in Trem2-deficient Alzheimer disease (AD) mice, status of neurofibrillary tangles remains uncertain; it may either increase or decrease (Jay et al., 2015; Wang et al., 2016).”
BackgroundKraller, M., Faßbender, J., Jabali, A., Kroeger, J. A., Fink, B., Popper, B., Ungerer, M., & Christlmeier, M. A. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01759-x · Cited by 17
“Some of the antibodies have been tested for their effects on cognition in the 5xFAD mouse model through behavioral studies [17, 20–22].”
King, M. W., Jacob, S. M., Sharma, A., Lawrence, J. H., & Musiek, E. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70885 · Cited by 11
“35 We co-stained sections withX34andHJ3.”
The Pathogenesis in Alzheimer's Disease: TREM2 as a Potential Target
Liu, G., Zhang, L., Fan, Y., & Ji, W. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206150 · Cited by 14
“In an AD model, TREM2-mediated early microglial responses reduced amyloid plaque transport and toxicity [150].”
BackgroundHarnessing microglia-based cell therapies for the treatment of neurodegenerative diseases
Walsh, A. E., & Lukens, J. R. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102552 · Cited by 16
Alternatives to amyloid for Alzheimer's disease therapies—a symposium report
Cable, J., Holtzman, D. M., Hyman, B. T., Tansey, M. G., Colonna, M., Kellis, M., Brinton, R. D., Albert, M., Wellington, C. L., Sisodia, S. S., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14371 · Cited by 13
Self-citationMicroglia at the Centre of Brain Research: Accomplishments and Challenges for the Future
Soares, N. L., & Vieira, H. L. A. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03456-1 · Cited by 18
Watson, Z., & Tang, S. (2022) · Cells · doi:10.3390/cells11121943 · Cited by 13
Var, S. R., Strell, P., Johnson, S. T., Roman, A., Vasilakos, Z., & Low, W. C. (2023) · Cell Transplantation · doi:10.1177/09636897231171001 · Cited by 15
Samuels, J. D., Lukens, J. R., & Price, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15981 · Cited by 23
“This results in the further compaction of A β into dense core plaques that are considered less damaging compared to diffuse A β fibrils (Wang et al., 2016 ; Yuan et al., 2016 ).”
InfluentialBasic Microglial Functions and How They Go Awry in Neurodegenerative Disease
McKinney, J. E., Bennett, M. L., & Bennett, F. C. (2026) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-042624-114332 · Cited by 16
Ji, P., Chen, Y., Ni, X., Miao, Q., & Hua, J. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16417 · Cited by 13
“28 – 30 Here, we suggested that knock-down of TREM2 signi fi cantly reduced the expression of lipid uptake and lipolysis-related genes in macrophages.”
BackgroundAnton, P. E., Maphis, N. M., Linsenbardt, D. N., & Coleman, L. G. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-81908-7_10 · Cited by 13
Kozyrev, N., Albers, S. S., Yang, J., Prado, V. F., Prado, M. A. M., Fonseca, G. J., Rylett, R. J., & Dekaban, G. A. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa093 · Cited by 14
Advances in proteomic phenotyping of microglia in neurodegeneration
Sunna, S. N., Bowen, C. A., Ramelow, C. C., Santiago, J. V., Kumar, P., & Rangaraju, S. (2023) · PROTEOMICS · doi:10.1002/pmic.202200183 · Cited by 13
Deciphering microglia phenotypes in health and disease
Balak, C. D., Han, C. Z., & Glass, C. K. (2024) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2023.102146 · Cited by 17
Pumo, A., & Legeay, S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148817 · Cited by 14
“These diffuse plaques feature longer and more tangled amyloid fibrils that are more exposed to neighboring nerve cells (Wang et al., 2016; Condello et al., 2015).”
Casali, B. T., Lin, L. W., Benedict, O., Zuppe, H. T., Marsico, E., & Reed-Geaghan, E. G. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03404-8 · Cited by 15
“To test this, we classified plaques based on morphology and compaction [28, 42, 47].”
Jiao, H., Ge, Y., Huang, L.-Y., Liu, Y., Wu, B., Lian, P., Hao, Y., Han, S., Li, Y., Wu, K., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00887-0 · Cited by 14
Self-citationMicroglia in Alzheimer’s Disease: A Favorable Cellular Target to Ameliorate Alzheimer’s Pathogenesis
Sumsuzzman, D. M., Uddin, M. S., Kabir, M. T., Hasana, S., Perveen, A., Alanazi, I. S., Albadrani, G. M., Abdel‐Daim, M. M., & Ashraf, G. M. (2022) · Mediators of Inflammation · doi:10.1155/2022/6052932 · Cited by 12
“In AD mouse models, parabiosis experiments revealed that, with a negligible contribution of infiltrating macrophages, microglia are responsible for increasing the number of myeloid cells observed in brains with plaque pathology [29].”
BackgroundToledano‐Díaz, A., Álvarez, M., & Tolédano, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221128703 · Cited by 12
Hu, H., Ma, L., Hu, H., Bi, Y., Ma, Y., Shen, X., Ou, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00383-5 · Cited by 11
Augusto‐Oliveira, M., Tremblay, M., & Verkhratsky, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_6 · Cited by 10
Novel insights into the role of TREM2 in cerebrovascular diseases
Awuah, W. A., Ben-Jaafar, A., Kong, J. S. H., Sanker, V., Shah, M. H., Poornaselvan, J., Frimpong, M., Imran, S., Alocious, T., Abdul-Rahman, T., et al. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149245 · Cited by 12
“In addition, TREM2 knockdown in a glioma cell line significantly downregulated C-X-C motif chemokine ligand ( CXCL ) 10, CXCR3 , matrix metal-lopeptidase (MMP) 2 and MMP9, leading to a reduction in glioma cell invasion and migration (Wang et al., 2016).”
Haploinsufficiency and Alzheimer’s Disease: The Possible Pathogenic and Protective Genetic Factors
Bagyinszky, E., & An, S. S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211959 · Cited by 10
Xu, B., Tang, C., Han, R., Zhu, C., Yang, Y., Li, H. J., Wu, N., & He, D. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251326044 · Cited by 14
“44 MG activation can be categorized into pro-in fl ammatory M1 and anti-in fl ammatory M2 subsets, which may vary across different stages and anatomical locations of the disease.”
Balancing Microglial Density and Activation in Central Nervous System Development and Disease
Wang, S., Pan, L., Sun, C., Ma, C., & Pan, H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050344 · Cited by 12
“In AD model 5 × FAD mice, TREM2 knockout leads to suppressed proliferation, reduced numbers, and phagocytosis of microglia, causing the expansion of A β plaques [105].”
Research Progress of Lipid Metabolism-Mediated Neuroinflammation in Alzheimer’s Disease
Shen, Y., Wang, X., Liu, X., Wang, G., Hou, X., & Zhou, X. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01648-9 · Cited by 12
“TREM2 dysfunction not only impairs cholesterol and myelin metabolism in the brain(Cantoni et al. 2015; Wang et al. 2016) but also significantly impedes the phagocytic and clearance ability of microglia to Aβ–lipoprotein complexes(Heneka et al. 2013).”
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
Rudman, M. D., Ulrich, J. D., & Holtzman, D. M. (2026) · Cell · doi:10.1016/j.cell.2026.06.006 · Cited by 18
Self-citationAnti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01069-3 · Cited by 10
“Indeed, microglia with low TREM2 activity fail to cluster around Aβ plaques, which results in increased neuritic damage [74, 79].”
BackgroundIron‐induced cellular in vitro neurotoxic responses in rat C6 cell line
Anuradha, U., Dey, M., Gautam, A. S., & Singh, R. K. (2022) · Environmental Toxicology · doi:10.1002/tox.23543 · Cited by 10
Roles of Microglia in AD Pathology
Gao, R., Wu, H., Li, Q., & Zhao, J. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230203112351 · Cited by 10
The roles of RACK1 in the pathogenesis of Alzheimer's disease
He, W., Shi, X., & Dong, Z. (2023) · Journal of Biomedical Research · doi:10.7555/jbr.37.20220259 · Cited by 11
Farfara, D., Sooliman, M., Avrahami, L., Royal, T. G., Amram, S., Rozenstein‐Tsalkovich, L., Trudler, D., Blanga‐Kanfi, S., Eldar-Finkelman, H., Pahnke, J., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02823-9 · Cited by 11
Headmasters: Microglial regulation of learning and memory in health and disease
Weinhard, L., d’Errico, P., & Tay, T. L. (2018) · AIMS molecular science · doi:10.3934/molsci.2018.1.63 · Cited by 12
“A similar analysis done in 4 months old 5XFAD mice showed that Aβ accumulation was quantitatively similar in the presence or absence of TREM2, but the plaques appeared more diffuse without TREM2 [174].”
Wang, K., & Zhang, W. (2021) · Synapse · doi:10.1002/syn.22196 · Cited by 11
“In AD patients, the autophagic pathway is also impaired in the microglia, which serve as barriers around plaques and limit their toxicity (Wang et al., 2016; Yuan et al., 2016).”
BackgroundChronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition
Blume, T., Deussing, M., Biechele, G., Peters, F., Zott, B., Schmidt, C., Franzmeier, N., Wind, K., Eckenweber, F., Sacher, C., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.854031 · Cited by 10
Self-citationLee, J., Ryu, S., Kim, H.-J., Jung, J., Lee, B., & Kim, T. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/390302 · Cited by 11
García‐Alberca, J. M., de Rojas, I., Sánchez‐Mejías, E., Garrido-Martín, D., Gonzalez-Palma, L., Jiménez, S., Pino‐Ángeles, A., Cruz-Gamero, J. M., Mendoza, S., Alarcón‐Martín, E., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231150 · Cited by 9
Sánchez-García, M. A., Lara-Ureña, N., March‐Díaz, R., Luis, C. O. S., Quiñones-Cañete, S., Mora-Romero, B., Cabello-Rivera, D., Muñoz-Cabello, A. M., Romero‐Molina, C., Romero‐Molina, C., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2244 · Cited by 11
Involvement of IL-10R/STAT3 pathway in amyloid β clearance by microlgia in Alzheimer's disease
Liu, H., Zhou, Y., & Song, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108263 · Cited by 17
Self-citationThe Implication of Glial Metabotropic Glutamate Receptors in Alzheimer’s Disease
de Lima, I. B. Q., & Ribeiro, F. M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211223140303 · Cited by 10
“For example, while Aβ-stimulated microglia can increase neurotoxicity through the release of TNF-α, NO, and ROS, inhibition of microglia response due to deficiency of the triggering receptor expressed on myeloid cells 2 (TREM2) is associated with increased toxicity of Aβ plaques [200-203].”
Yao, J., He, Z., You, G., Liu, Q., & Li, N. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080402 · Cited by 11
Friends and Foes in Alzheimer’s Disease
Pauwels, E. K. J., & Boer, G. J. (2023) · Medical Principles and Practice · doi:10.1159/000534400 · Cited by 12
“Triggering receptor expressed in myeloid cells 2 (TREM2) is a receptor that recognizes the accumulation of β A and its neuronal toxicity [28].”
BackgroundLong‐term recruitment of peripheral immune cells to brain scars after a neonatal insult
Bolini, L., Campos, R. M. P., Spiess, D. A., Lima‐Rosa, F. L., Dantas, D. P., Conde, L., Méndez‐Otero, R., Vale, A. M., & Pimentel‐Coelho, P. M. (2023) · Glia · doi:10.1002/glia.24490 · Cited by 10
“…whether these immunoglobulins circulating cells entering the brain in parabionts is consistently low in the absence of brain injury or in models of neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis (Ajami et al., 2007; Villeda et al., 2011; Wang et al., 2016).”
BackgroundPotential Alzheimer’s disease drug targets identified through microglial biology research
Lepiarz‐Raba, I., Hidayat, T., Hannan, A. J., & Jawaid, A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2335210 · Cited by 10
“Abundantly expressed [108,109], TREM2 enables microglia to surround Aβ plaques and limit Aβ seeding [110,111].”
BackgroundMicroglia-Associated Neuroinflammation in Alzheimer’s Disease and Its Therapeutic Potential
Shah, S., & Jain, H. (2024) · Neuroglia · doi:10.3390/neuroglia5040029 · Cited by 11
Cell death in development, maintenance, and diseases of the nervous system
Mercau, M. E., Patwa, S., Bhat, K., Ghosh, S., & Rothlin, C. V. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00938-4 · Cited by 9
Cai, C., Gu, C., Meng, C., He, S., Lhamo, T., Draga, D., Zheng, Z., & Qiu, Q. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03777-0 · Cited by 9
“Glia are NVU cells essential for the accumulation and clearance of Aβ plaques and neurofibrillary tangles in the brain of patients with AD [96].”
Cao, F., Zhang, P., Chi, Y., Wang, Y., Xu, L., & Zhang, D. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04375-1 · Cited by 11
Self-citationRuan, E., Lin, J., Zhao, C., Sheng, Q., Chen, L., He, J., Duan, X., Qin, Y., Xing, T., Yang, S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci178349 · Cited by 8
“TREM2 is a pivotal regulator of microglial state, but its effects on neurodegeneration appear to be dependent on the disease contexts (37–40).”
Advances of therapeutic strategies for Alzheimer’s disease
Guo, X., Yue, R.-Z., Cui, Z., Wang, S., Jia, T., Li, W., Zhang, W., Shan, L., & Li, C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13456-8 · Cited by 10
“Another experiment carried out in 5 × FAD mice with TREM2 deficiency also indicated that the protective role of TREM2 in AD is enabling microglia to surround and modify the Aβ plaque structure, thereby restricting neuronal damage [141].”
Emerging non-proinflammatory roles of microglia in healthy and diseased brains
Sun, Y., Che, J., & Zhang, J. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110664 · Cited by 11
“TREM2 is an immunoglobulin superfamily receptor that is expressed on the microglial surface of the brain (Ulland and Colonna, 2018).”
BackgroundInfluentialLim, S., Tran, D. N., Kieu, Z., Chen, C., Villanueva, E., Ghiaar, S., Gallup, V., Zumkehr, J., Cribbs, D. H., Rodríguez‐Ortiz, C. J., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01894-6 · Cited by 8
Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 9
Mechanisms of increased Alzheimer’s disease pathology with R47H and R62H TREM2 variants
Fancy, N. N., Willumsen, N., Chau, V. M. N., Boulger, S. L., Whitwell, H. J., Wang, W., Avot, B., Thomas, M., Talbot-Martin, J., Tsartsalis, S., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03036-z · Cited by 8
Marino, K. M., Squirrell, J. M., Chacko, J. V., Watters, J. J., Eliceiri, K. W., & Ulland, T. K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.12.540407 · Cited by 8
Self-citationChanges of the Primary Cilia in Alzheimer's Disease Pathogenesis
Guo, A., Wang, H., Zhang, Y., & Huang, H. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70125 · Cited by 7
“In AD pathology, microglia play a crucial role in clearing Aβ depositions and inhibiting Tau hyperphosphorylation (Wang et al. 2016).”
Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2019) · doi:10.1101/639054 · Cited by 7
A systematic review of the role of TREM2 in Alzheimer’s disease
Yin, Y., Yang, H.-C., Li, R., Wu, G., Qin, Q., & Tang, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003000 · Cited by 11
“[34] Thus, the origin of TREM2-associated microglia remains enigmatic.”
Microglia in the aged brain develop a hypoactive molecular phenotype after surgery
Yin, Z., Leonard, A. K., Porto, C. M., Xie, Z., Silveira, S., Culley, D. J., Butovsky, O., & Crosby, G. J. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03307-0 · Cited by 10
Canet, G., Zussy, C., Vitalis, M., Morin, F., Chevallier, N., Hunt, H., Claeysen, S., Blaquière, M., Marchi, N., Planel, E., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17457 · Cited by 9
“TREM2 is essential for promoting microglial association with amyloid plaques and proliferation around them (Hansen et al., 2018; Jay et al., 2015; Wang et al., 2016).”
Investigation of patterns and associations of neuroinflammation in cognitive impairment
Gan, R., Xie, H., Zhao, Z., Wu, X., Wang, R., Wu, B., Chen, Q., & Jia, Z. (2025) · Cerebral Cortex · doi:10.1093/cercor/bhaf013 · Cited by 7
Zhang, J., He, Y., Yang, P., Zhang, H., Tong, Y., Jiang, L., Li, Z., Yan, M., Li, X., Yang, Q., et al. (2025) · Advanced Science · doi:10.1002/advs.202515877 · Cited by 9
Evolving insights into the identity and function of dark microglia
Flury, A., St-Pierre, M.-K., Ayata, P., & Tremblay, M.-È. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2025.11.002 · Cited by 8
Zhou, X., Liu, Z., Li, S., Song, Y., Sun, M., Si, Z., & Zhu, W. (2025) · Inflammation Research · doi:10.1007/s00011-025-02155-9 · Cited by 9
“Brain tissues from Trem2 −/− 5XFAD mice exhibit reduced numbers of microglia, which fail to effectively encapsu - late the plaques, resulting in looser plaque morphology, increased diffusion, and consequently exacerbated synaptic damage and neurotoxicity [39 ].”
Immune signaling and function in neurodegeneration
Latour, Y. L., & McGavern, D. B. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199850 · Cited by 10
“In line with these findings, TREM2 deficiency in 5xFAD mice increased A β burden, suppressed microglial activation, and exacerbated disease progression (126, 127).”
Attack of the Clones: Microglia in Health and Disease
Manjally, A. V., & Tay, T. L. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.831747 · Cited by 8
Roles of microglial membranes in Alzheimer's disease
Shin, J., & Lee, J. C. (2020) · Current topics in membranes · doi:10.1016/bs.ctm.2020.08.007 · Cited by 7
“The presence of triggering receptor expressed on myeloid cells 2 (TREM2) in microglia is essential for microglia to surround and alter amyloid-β peptide (Aβ) plaque structure, thereby limiting neuritic damage to protect from AD (Wang et al., 2016).”
BackgroundA protective signal between the brain’s supporting cells in Alzheimer’s disease
Barron, J. J., & Molofsky, A. V. (2021) · Nature · doi:10.1038/d41586-021-01870-7 · Cited by 8
Transcriptome and Translatome Regulation of Pathogenesis in Alzheimer’s Disease Model Mice
Eastman, G., Sharlow, E. R., Lazo, J. S., Bloom, G. S., & Sotelo-Silveira, J. R. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215357 · Cited by 9
Mildner, A. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.205090 · Cited by 7
“Trem2 was further shown to be selectively expressed by microglia in proximity to Aβ plaques and identified as a receptor for several lipids that are exposed during Aβ deposition as well as during glial and neuronal cell death (Wang et al., 2016).”
Rossi, E., Mracsko, E. Z., Papadimitropoulos, A., Allafi, N., Reinhardt, D., Mehrkens, A., Martín, I., Knuesel, I., & Scherberich, A. (2018) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2018.0061 · Cited by 8
New “programmers” in tissue macrophage activation
Aschenbrenner, A. C., & Schultze, J. L. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-1943-9 · Cited by 7
TAM-ping down amyloid in Alzheimer’s disease
Wilson, E. N., & Andreasson, K. I. (2021) · Nature Immunology · doi:10.1038/s41590-021-00918-0 · Cited by 7
Metadata
- Authors
- Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., Cella, M., Grutzendler, J., DeMattos, R. B., Cirrito, J. R., Holtzman, D. M., & Colonna, M.
- Affiliations
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- Yale University (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-04-18
- Volume
- 213
- Issue
- 5
- Pages
- 667-675
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4854736
- OpenAlex
- W2339534121
- Cited by
- 840
- References
- 32
- Citations by year
- 2026: 62 · 2025: 76 · 2024: 86 · 2023: 106 · 2022: 114 · 2021: 102 · 2020: 93 · 2019: 73 · 2018: 61 · 2017: 50 · 2016: 16
- FWCI
- 36.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Eli Lilly and Company
- National Institutes of Health (RF1 AG05148501, 5T32CA009547-30, AG047644)
- National Multiple Sclerosis Society (RG4687A1/1)
- Cure Alzheimer’s Fund
- JPB Foundation
- Knight Alzheimer’s Disease Research Center (P50 AG005681-30)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- TREM2, microglia, amyloid plaques, Alzheimer's disease, parabiosis, 5xFAD mice, TREM2 deficiency, lipid microenvironment, peripheral blood monocytes
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Membrane Glycoproteins, Monocytes, Receptors, Immunologic, Amyloid beta-Peptides, Neurites, Microglia, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.